NCT07838649Not yet recruitingPhase 1
Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity
PET Imaging of Chemotherapy-Induced Cardiotoxicity
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
This study is a single center, phase 1 clinical imaging study designed to assess the role of 68Ga-Galmydar Positron Emission Tomography (PET) imaging for detection of cardiotoxicity in human subjects with breast cancer or lymphoma undergoing treatment with anthracycline for cancer therapy.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 17 Sept 2026
- Start date
- 1 Nov 2026
- Primary completion date
- 12 Dec 2029
- Lead sponsor
- Washington University School of Medicine
- Diseases
- Heart failure, Hodgkin lymphoma
- NCT number
- NCT07838649
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 36
- From 1 Nov 2026 to the primary completion date, 12 Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior exposure to anthracyclines or other cardiotoxic drug
- Contraindications to anthracycline chemotherapy
- Contraindications to MR imaging (ferromagnetic implants, pacemaker, brain aneurysm clips, shrapnel, claustrophobia, etc.)
Other illness
- Patients with history of myocardial infarction
- Any condition that in the opinion of the Principal Investigator or designee could increase risk to the participant, limit the participant's ability to tolerate the research procedures or interfere with collection of the data such as:
- Inability to lie still or unable to tolerate a supine position with arms up over the head or down at sides for up to a 60-minute PET scan due to chronic back/shoulder pain or arthritis as assessed by physical examination and/or medical history
Lab values
- Patients with fasting blood sugar \>200 mg/dL or \<70 mg/dL and symptomatic
- Pregnant or lactating. All female subjects of childbearing potential must have a documented negative pregnancy test (serum or urine hCG) performed within 24 hours immediately prior to the administration of 68Ga-Galmydar or documented post-menopausal defined as the cessation of menses for ≥ 12 months or documentation of having a bilateral oophorectomy and/or hysterectomy.
Other
- Inability to receive and sign informed consent
Who the study is looking for
- Men and women, 21-99 years of age and any race
- Normal left ventricular function (left ventricular ejection fraction (LVEF) \>50%) as determined by echocardiography
- HER2 positive or negative breast cancer patients or lymphoma patients
- Designated to receive standard of care (SOC) treatment with an anthracycline-containing regimen including combination therapy
- Patients willing to adhere to fasting for 15 hours before 18F-FDG PET imaging studies (if applicable)
Age in the registry: 21 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Washington University School of Medicine Coordinator of this site? Confirm its status | St Louis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.